The study conducted by researchers at Dana-Farber Cancer Institute, and published in JAMA Oncology, found a siginificant increase in progression-free survival in men who initiated statin therapy along with androgen deprivation for their prostate cancer.
Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy (ADT) for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
In a study published online today by JAMA Oncology, the researchers report that men who had been taking statins since the start of androgen deprivation therapy went a median of 27.5 months before their disease began to worsen, compared to 17.4 months for men who didn't take statins. The trial involved 926 patients, 70% of whom had their disease progress during a 6-year period.
Read the complete news on EurekAlert!: http://bit.ly/1cap5Cy